Hussman Strategic Advisors Inc. Sells 4,650 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Hussman Strategic Advisors Inc. reduced its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 59.6% in the fourth quarter, Holdings Channel reports. The fund owned 3,150 shares of the pharmaceutical company’s stock after selling 4,650 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Vertex Pharmaceuticals were worth $1,282,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. LSV Asset Management lifted its stake in Vertex Pharmaceuticals by 206.3% in the first quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock valued at $1,240,000 after purchasing an additional 3,200 shares during the last quarter. Synovus Financial Corp raised its stake in shares of Vertex Pharmaceuticals by 9.6% in the first quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock valued at $1,759,000 after buying an additional 590 shares during the period. Cibc World Market Inc. lifted its position in shares of Vertex Pharmaceuticals by 69.4% during the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock valued at $1,728,000 after buying an additional 2,713 shares during the last quarter. Sei Investments Co. grew its stake in shares of Vertex Pharmaceuticals by 28.4% during the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock worth $11,756,000 after acquiring an additional 9,761 shares during the period. Finally, Cetera Investment Advisers increased its holdings in Vertex Pharmaceuticals by 4.0% in the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now directly owns 74,364 shares in the company, valued at $31,250,727.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. In the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

VRTX has been the topic of several recent research reports. Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. JPMorgan Chase & Co. raised their price objective on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Canaccord Genuity Group reissued a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Royal Bank of Canada increased their target price on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Finally, Truist Financial lifted their price target on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

View Our Latest Stock Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of Vertex Pharmaceuticals stock opened at $394.28 on Monday. The company has a 50 day simple moving average of $413.60 and a two-hundred day simple moving average of $397.73. The firm has a market cap of $101.91 billion, a PE ratio of 28.39, a PEG ratio of 1.86 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 1 year low of $316.43 and a 1 year high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the previous year, the firm posted $3.33 EPS. Analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

See Also

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.